[go: up one dir, main page]

BR9916893A - Tratamento - Google Patents

Tratamento

Info

Publication number
BR9916893A
BR9916893A BR9916893-6A BR9916893A BR9916893A BR 9916893 A BR9916893 A BR 9916893A BR 9916893 A BR9916893 A BR 9916893A BR 9916893 A BR9916893 A BR 9916893A
Authority
BR
Brazil
Prior art keywords
hepatitis
treatment
virus
vaccine
antiviral agent
Prior art date
Application number
BR9916893-6A
Other languages
English (en)
Inventor
Gillian Frances Atkinson
Ronald James Boon
Pierre G Vandepapeliere
Martine Anne Cecil Wettendorff
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of BR9916893A publication Critical patent/BR9916893A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "TRATAMENTO". Esta invenção forneceum pacote farmacêutico que compreende como os ingredientesativos (1) um agente antiviral ativo contra o vírus da hepatite B e(2) uma vacina para a profilaxia e/ou para o tratamento deinfecção de hepatite B, sendo os ingredientes ativos para usosimultâneo ou seq³encial. Os componentes preferidos são umanálogo de nucleosídeo como o agente antiviral, junto com umavacina para o vírus da hepatite B que compreende um antígenode superfície do vírus da hepatite B.
BR9916893-6A 1999-01-12 1999-12-21 Tratamento BR9916893A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12
PCT/EP1999/010295 WO2000041463A2 (en) 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents

Publications (1)

Publication Number Publication Date
BR9916893A true BR9916893A (pt) 2001-11-20

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916893-6A BR9916893A (pt) 1999-01-12 1999-12-21 Tratamento

Country Status (19)

Country Link
EP (1) EP1140163A2 (pt)
JP (1) JP2002534438A (pt)
KR (1) KR20010090011A (pt)
CN (1) CN1391482A (pt)
AR (1) AR022250A1 (pt)
AU (1) AU760574B2 (pt)
BR (1) BR9916893A (pt)
CA (1) CA2359110A1 (pt)
CO (1) CO5241355A1 (pt)
CZ (1) CZ20012544A3 (pt)
HK (1) HK1041434A1 (pt)
HU (1) HUP0105070A2 (pt)
IL (1) IL144186A0 (pt)
NO (1) NO20013337L (pt)
NZ (1) NZ512890A (pt)
PL (1) PL349347A1 (pt)
TR (1) TR200102024T2 (pt)
WO (1) WO2000041463A2 (pt)
ZA (1) ZA200105690B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
CN102198266A (zh) 1998-07-31 2011-09-28 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
BRPI0208183B8 (pt) 2001-03-22 2021-05-25 Sugiyama Haruo peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
WO2003028758A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003028757A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
BR0315810A (pt) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
CN100443117C (zh) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
AR065504A1 (es) * 2007-02-28 2009-06-10 Ct Ingenieria Genetica Biotech Terapia combinada para el tratamiento de la hepatitis b cronica. uso.
EP3903815A4 (en) 2018-12-24 2022-09-28 Grand Theravac Life Science (Nanjing) Co., Ltd. PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF HEPATITIS B, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
EP4321173A4 (en) * 2021-04-07 2025-08-20 Denka Company Ltd ADJUVANT ACTIVITY ACTIVATOR AND ADJUVANT COMPOSITION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48175A1 (en) * 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
PL343429A1 (en) * 1998-03-09 2001-08-13 Smithkline Beecham Biolog Combined vaccine compositions

Also Published As

Publication number Publication date
KR20010090011A (ko) 2001-10-17
CO5241355A1 (es) 2003-01-31
NO20013337D0 (no) 2001-07-05
WO2000041463A2 (en) 2000-07-20
TR200102024T2 (tr) 2001-12-21
ZA200105690B (en) 2002-09-25
WO2000041463A3 (en) 2000-11-09
AU760574B2 (en) 2003-05-15
HK1041434A1 (zh) 2002-07-12
JP2002534438A (ja) 2002-10-15
CA2359110A1 (en) 2000-07-20
IL144186A0 (en) 2002-05-23
NZ512890A (en) 2003-09-26
NO20013337L (no) 2001-08-17
EP1140163A2 (en) 2001-10-10
PL349347A1 (en) 2002-07-15
CN1391482A (zh) 2003-01-15
CZ20012544A3 (cs) 2002-01-16
AR022250A1 (es) 2002-09-04
AU2100900A (en) 2000-08-01
HUP0105070A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
TWI317735B (en) Methods and compositions for treating hepatitis c virus
MXPA02006679A (es) Composicion farmaceutica.
BR9916893A (pt) Tratamento
FI20001231A7 (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
BR0011433B1 (pt) Compostos de imidazoquinolinas substituídas com sulfonamida e sulfamida e composição farmaceutica cotendo os mesmos
BR0206614A (pt) Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
HRP20040059B1 (en) Treatment of nail infections with no
AR002255A1 (es) Una composicion que comprende una formulacion de antigeno microfluidizada y usos de dicha formulacion.
BR0108499A (pt) Agente terapêutico para hepatite c
ES2179110T3 (es) Succinato 4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-ciclopenteno-1-metanol como agente antiviral.
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
PE61699A1 (es) Composicion farmaceutica de lamivudina
ES2041243T3 (es) Aplicacion de por lo menos un principio activo inhibidor o destructor de por lo menos un ser vivo unicelular o virus.
BR0206775A (pt) Uso de um medicamento para tratar um indivìduo infectado com hiv, por combinação de imunização com interrupção estruturada do tratamento anti-retrovirótico
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
BR9710206A (pt) Uso de um agente de interleucina-8 e formulação farmacéutica antiviral
ATE253938T1 (de) Pharmazeutische kombination von antiviralen wirkstoffen
BR9809127A (pt) Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
CL2004001291A1 (es) Composicion farmaceutica que comprende compuestos carbociclicos y heterociclicos; y su uso para el tratamiento o profilaxis de la infeccion por influenza.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O E 7O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.